Baron Health Care Fund Adds Repligen, Citing AI Moat and 30% Cell Therapy Growth
Baron Health Care Fund’s Institutional Shares rose 13.10% in Q4 2025 versus an 11.92% gain for the Russell 3000 Health Care Index and full-year returns of 10.28%. The fund added Repligen Corporation, whose stock fell 16.28% over one month but offers a $7.862 billion market cap and potential to double revenue in five years.
1. Fund Performance and Comparison
In Q4 2025, Baron Health Care Fund’s Institutional Shares delivered a 13.10% gain, outperforming the Russell 3000 Health Care Index’s 11.92% rise and far ahead of the Russell 3000’s 2.40% advance. For the full year, the fund returned 10.28% versus 14.56% and 17.15% for the healthcare and broad-market benchmarks, respectively.
2. Repligen Stock Metrics
Repligen Corporation shares have declined 16.28% over the past month and 10.50% over the last 52 weeks. As of February 5, 2026, its stock closed at $139.66 with a market capitalization of $7.862 billion, reflecting recent volatility amid broader biotech market fluctuations.
3. Rationale for Adding Repligen
Baron highlighted Repligen’s leadership in bioprocessing tools, targeting monoclonal antibodies (8–10% market growth) and cell and gene therapies (over 30% growth). The fund expects Repligen’s in-line process analytics, AI-driven data moat, strong acquisition track record and reshoring tailwinds to support a doubling of revenue and a 1,000 bp EBITDA margin expansion over five years.